Page 33 - The prevalence of the Val66Met polymorphism in musicians: Possible evidence for compensatory neuroplasticity from a pilot study

Lewis and Green Genome Medicine (2021) 13:14 Page 10 of 10

65. Pravettoni G, Gorini A. A P5 cancer medicine approach: why personalized 86. Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS,
medicine cannot ignore psychology. J Eval Clin Pract. 2011;17:594–6. Cruchaga C, et al. Assessment of racial disparities in biomarkers for
https://doi.org/10.1111/j.1365-2753.2011.01709.x. Alzheimer disease. JAMA Neurol. 2019;76:264–73. https://doi.org/10.1001/
66. Godard B, ten Kate L, Evers-Kiebooms G, Aymé S. Population genetic jamaneurol.2018.4249.
screening programmes: principles, techniques, practices, and policies. Eur J 87. Sankar P, Cho MK, Condit CM, Hunt LM, Koenig B, Marshall P, et al. Genetic
Hum Genet. 2003;11:S49–87. https://doi.org/10.1038/sj.ejhg.5201113. research and health disparities. JAMA J Am Med Assoc. 2004;291:2985–9.
67. Junegst E, Flatt M, Setterson R. Personalized genomic medicine and the https://doi.org/10.1001/jama.291.24.2985.
rhetoric of empowerment. Hastings Cent Rep. 2012;42:34–40. https://doi. 88. Roberts DE. Law, race, and biotechnology: toward a biopolitical and
org/10.1002/hast.65. transdisciplinary paradigm. Annu Rev Law Soc Sci 2013;9:149–166. doi:
68. Chief Medical Officer annual report 2016: generation genome. GOVUK 2016. https://doi.org/10.1146/annurev-lawsocsci-102612-134009.
https://www.gov.uk/government/publications/chief-medical-officer-annual- 89. Vyas DA, Eisenstein LG, Jones DS. Hidden in plain sight — reconsidering the
report-2016-generation-genome. Accessed 16 Sept 2019 use of race correction in clinical algorithms. N Engl J Med. 2020;383:874–82.
69. Wikler D. Personal and social responsibility for health. Ethics Int Aff N Y. https://doi.org/10.1056/NEJMms2004740.
2002;16:47 http://dx.doi.org.ezp-prod1.hul.harvard.edu/10.1111/j.1747-7093.2 90. Yu J-H, Taylor JS, Edwards KL, Fullerton SM. What are our AIMs?
002.tb00396.x. Interdisciplinary perspectives on the use of ancestry estimation in disease
70. Guttman N, Salmon CT. Guilt, fear, stigma and knowledge gaps: ethical research. AJOB Prim Res. 2012;3:87–97. https://doi.org/10.1080/21507716.
issues in public health communication interventions. Bioethics. 2004;18:531– 2012.717339.
52. https://doi.org/10.1111/j.1467-8519.2004.00415.x. 91. Singh I, Rose N. Biomarkers in psychiatry. Nature. 2009;460:202–7. https://
71. Witteman HO, Fuhrel-Forbis A, Wijeysundera HC, Exe N, Dickson M, doi.org/10.1038/460202a.
Holtzman L, et al. Animated randomness, avatars, movement, and 92. Dissecting the phenotype in genome-wide association studies of psychiatric
personalization in risk graphics. J Med Internet Res. 2014;16:e80. https://doi. illness. Br J Psychiatry J Ment Sci 2009;195:97–99. doi: https://doi.org/10.
org/10.2196/jmir.2895. 1192/bjp.bp.108.063156.
72. Bonner C, Jansen J, McKinn S, Irwig L, Doust J, Glasziou P, et al. 93. Zheutlin AB, Dennis J, Karlsson Linnér R, Moscati A, Restrepo N, Straub P,
Communicating cardiovascular disease risk: an interview study of General et al. Penetrance and pleiotropy of polygenic risk scores for schizophrenia
Practitioners’ use of absolute risk within tailored communication strategies. in 106,160 patients across four health care systems. Am J Psychiatry. 2019;
BMC Fam Pract. 2014;15:106. https://doi.org/10.1186/1471-2296-15-106. 176:846–55. https://doi.org/10.1176/appi.ajp.2019.18091085.
73. Vassy JL, Christensen KD, Slashinski MJ, Lautenbach DM, Raghavan S, 94. Palk AC, Dalvie S, de Vries J, Martin AR, Stein DJ. Potential use of clinical
Robinson JO, et al. ‘Someday it will be the norm’: physician perspectives on polygenic risk scores in psychiatry – ethical implications and
the utility of genome sequencing for patient care in the MedSeqProject. communicating high polygenic risk. Philos Ethics Humanit Med. 2019;14:4.
Pers Med. 2015;12:23–32. https://doi.org/10.2217/pme.14.68. https://doi.org/10.1186/s13010-019-0073-8.
95. Khoury MJ, Gwinn ML, Glasgow RE, Kramer BS. A population approach to
74. Thaler RH, Sunstein CR. Nudge: improving decisions about health, wealth,
precision medicine. Am J Prev Med. 2012;42:639–45. https://doi.org/10.1016/
and happiness. Revised&Expanded edition. New York: Penguin Books; 2009.
j.amepre.2012.02.012.
75. Noggle R. The Ethics of Manipulation. In: Zalta EN, editor. Stanf. Encycl.
96. Falconer DS. The inheritance of liability to certain diseases, estimated from
Philos. Summer 2018, Metaphysics Research Lab, Stanford University; 2018.
the incidence among relatives. Ann Hum Genet. 1965;29:51–76. https://doi.
https://plato.stanford.edu/entries/ethics-manipulation/.
org/10.1111/j.1469-1809.1965.tb00500.x.
76. Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are
under-represented in clinical trials: a review of the literature. Health 97. Plomin R. Blueprint: how DNA makes us who we are. MIT Press 2018.
Soc Care Community. 2004;12:382–8. https://doi.org/10.1111/j.1365-2524. https://mitpress.mit.edu/books/blueprint. Accessed 28 Oct 2018
2004.00507.x. 98. Suter S. The problems of liminal states, line drawing, and false dichotomies.
J Law Biosci. 2015;2:736–41. https://doi.org/10.1093/jlb/lsv047.
77. Duconge J, Ruaño G. Preventing the exacerbation of health disparities by
99. McGee A. Using the therapy and enhancement distinction in law and
iatrogenic pharmacogenomic applications: lessons from warfarin.
policy. Bioethics. 2020;34:70–80. https://doi.org/10.1111/bioe.12662.
Pharmacogenomics. 2018;19:875–81. https://doi.org/10.2217/pgs-2018-0055.
78. Christensen KD, Roberts JS, Royal CDM, Fasaye G-A, Obisesan T, Cupples LA,
et al. Incorporating ethnicity into genetic risk assessment for Alzheimer Publisher’sNote
disease: the REVEAL study experience. Genet Med Off J Am Coll Med Genet. Springer Nature remains neutral with regard to jurisdictional claims in
2008;10:207–14. https://doi.org/10.1097/GIM.0b013e318164e4cf. published maps and institutional affiliations.
79. Genetics for all. Nat Genet 2019;51:579–579. https://doi.org/10.1038/s41588-
019-0394-y.
80. The “All of Us” Research Program. N Engl J Med 2019;381:668–676. doi:
https://doi.org/10.1056/NEJMsr1809937.
81. Nary FC, Santos RD, Laurinavicius AG, Conceição RD de O, de Carvalho JAM.
Relevance of prehypertension as a diagnostic category in asymptomatic
adults. Einstein 2013;11:303–309. https://doi.org/10.1590/S1679-
45082013000300008.
82. Gijsberts CM, Seneviratna A, Bank IEM, den Ruijter HM, Asselbergs FW,
Agostoni P, et al. The ethnicity-specific association of biomarkers with the
angiographic severity of coronary artery disease. Neth Heart J. 2016;24:188–
98. https://doi.org/10.1007/s12471-015-0798-y.
83. Veeranna V, Zalawadiya SK, Niraj A, Kumar A, Ference B, Afonso L.
Association of novel biomarkers with future cardiovascular events is
influenced by ethnicity: results from a multi-ethnic cohort. Int J Cardiol.
2013;166:487–93. https://doi.org/10.1016/j.ijcard.2011.11.034.
84. Rappoport N, Paik H, Oskotsky B, Tor R, Ziv E, Zaitlen N, et al. Comparing
ethnicity-specific reference intervals for clinical laboratory tests from EHR data.
J Appl Lab Med. 2018;3:366–77. https://doi.org/10.1373/jalm.2018.026492.
85. Omuse G, Maina D, Mwangi J, Wambua C, Kanyua A, Kagotho E, et al.
Comparison of equations for estimating glomerular filtration rate in
screening for chronic kidney disease in asymptomatic black Africans: a cross
sectional study. BMC Nephrol. 2017;18:369. https://doi.org/10.1186/s12882-
017-0788-y.